8. Bibliografia

  1. Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother 2001; 35: 1016-1019.
  2. Poels PJ, Gabreels FJ. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993; 95: 175-192.
  3. Dayer-Berenson L. Rhabdomyolysis: a comprehensive guide. ANNA J 1994; 21: 15-18.
  4. Grob D. Rhabdomyolysis and drug-related myopathies. Curr Opin Rheumatol 1990; 2: 908-915.
  5. Wortmann RL. Inflammatory diseases of muscle and other myopathies. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1997: 1193-1196.
  6. Hamer R. When exercise goes awry: exertional rhabdomyolysis. South Med J 1997; 90: 548-551.
  7. Carriere SR, Elsworth T. Found down: compartment syndrome, rhabdomyolysis, and renal failure. J Emerg Nurs 1998; 24: 214-217.
  8. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28-34. J.
  9. Ziegler O, Drouin P. Safety, tolerability, and efficacy of simvastatin and fenofibrate - a multicenter study. Simvastatin-Fenofibrate Study Group. Cardiology 1990; 77 (suppl): 50-57
  10. Kiely M, Kiely D. Rhabdomyolysis. J Emerg Nurs 1986; 12: 153-156.
  11. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-385.
  12. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 1996; 1: 11-24.
  13. Steiner A, et al. Comparative review of the adverse effects of treatments for hyperlipidemia. Drug Saf 1991; 6: 118-130.
  14. Hsu I, et al. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743-759.
  15. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3-11. D.
  16. Herman R. Drug interactions and the statins. Can Med Assoc J 1999; 161: 1281-1286.
  17. Stalenhoef AF, et al. Efficacy and tolerability of simva-statin (MK-733). Am J Med 1989; 87: 39-43.
  18. Jones PH, Hyperlipoproteinemias. In: Rakel RE, ed. Conn's current therapy 2000. Philadelphia: WB Saunders, 2000: 578-584.
  19. Shetty HGM, et al. Disorders of muscle, bone, and connective tissue. In: Davies DM, Ferner RE, De Glanville H, eds. Davies textbook of adverse drug reactions. London: Chapman and Hall, 1998:541-543.
  20. Christians U, et al. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol Ther 1998; 80: 1-34.
  21. Maron DJ, et al. Current perspectives on statins. Circulation 2000; 101: 207-213.
  22. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52: 1639-1645.
  23. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37.
  24. Bottorff M. "Fire and forget?"-Pharmacological considerations in coronary care. Atherosclerosis 1999; 147 suppl.1 S.: 23-30.
  25. Berland Y, et al. Rhabdomyolysis with simvastatin use (letter). Nephron 1991; 57: 365-366.
  26. Omar MA et al. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107.
  27. Corsini A, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.
  28. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999; 65: 1329-1337.
  29. Shimada T, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423
  30. Duell PB, et al. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368-369.
  31. Maltz HC, et al. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176-1179.
  32. Smit JW, et al. Treatment of hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995; 76: 126-128. A.
  33. Spence JD, et al. Pharmacokinetics of the combination of fluvastatin with gemfibrozil. Am J Cardiol 1995; 76: 80-83. A.
  34. Muratti EN, et al. Fluvastatin in familial hyper-cholesterolemia: a cohort analysis of the response to combination treatment. Am J Cardiol 1994; 73: 30-38. D.
  35. Pierce LR, et al. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-75.
  36. Norman DJ, et al. Myolysis and acute renal failure in heart transplant patients receiving lovastatin (letter). N Engl J Med 1988; 318: 46-47.
  37. East C, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988; 318: 47-48.
  38. Corpier CL, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-241.
  39. Manoukian AA, et al. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 1990; 36: 2145-2147.
  40. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992; 26: 190-192.
  41. Fernandez-Zatarain G, et al. Rhabdomyolysis and acute renal failure associated with lovastatin (letter). Nephron 1994; 66: 483-484.
  42. Beisenbach G, et al. Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial Transplant 1996; 11: 2059-2060.
  43. Chu PH, et al. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy. Jpn Heart J 1997; 38: 541-555.
  44. Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroentorol 1995; 21: 340-341.
  45. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112: 228-230.
  46. Goldman JA, et al. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis (letter). Arthritis Rheum 1989; 32: 358-359.
  47. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990; 66: 294-296.
  48. De Alava E, et al. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants (letter). Nephron 1994; 66: 242-243.
  49. Knoll RW, et al. Rhabdomyolysis and acute renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibrozil. Conn Med 1993; 57: 593-594.
  50. Hill MD, Bilbao JM. Case of the month: February 1999 - 54-year-old man with severe muscle weakness. Brain Pathol 1999; 9: 607-608.
  51. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lova-statin and the antifungal agent itraconazole (letter). N Engl J Med 1995; 333: 664-665.
  52. Chrysanthopolous C, Kounis N. Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine. Br Med J 1992; 304: 1225.
  53. Spach DH, et al. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213-215.
  54. Ayanian JZ, et al. Lovastatin and rhabdomyolysis (letter). Ann Intern Med 1988; 109: 682-683.
  55. Wong PW, et al. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998; 91: 202-205.
  56. Alejandro DR, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol 1994; 5: 153-160.
  57. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997; 31: 859-863.
  58. Landesman KA, et al. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 1999; 63: 455-457.
  59. Dallaire M, Chamberland M. [Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline]. Can Med Assoc J 1994; 150: 1991-1994.
  60. Hermida LI, et al. [Rhabdomyolysis in a patient treated with lovastatin and cyclosporine] (letter). Ann Med Interna 1997; 14: 488.
  61. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988; 318: 48.
  62. Ahamad S. Diltiazem myopathy. Am Hearth J 1993; 126: 1494-1495.
  63. Horsmans Y, et al. Effects of simvastatin and pravastatin on 6-beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res 1993; 28: 243-248.
  64. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917.
  65. Franc S, et al. Rhabdomyolysis in patients with pre-existing myopathy given lipid lowering drugs. Presse Med 1997; 26: 1855-1858.
  66. Perault MC, et al. Rhabdomyolysis related to ingestion of pravastatin (Vasten) (letter). Therapie 1993; 48: 487.
  67. Rosenberg AD, et al. Intraoperative rhabdomyolysis in a patient receiving prava-statin, a 3-hydroxy-3-methyglutaryl coenzyme A (HMG Co A) reductase inhibitor. Anesth Analg 1995; 81: 1089-1091.
  68. Takei A, Chiba S. Rhabdomyolysis associated with pravastatin treatment for major depression (letter). Psychiatry Clin Neurosci 1999; 53: 539.
  69. Hino I, et al. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum 1996; 39: 1259-1260.
  70. Colombo P, et al. Acute rhabdomyolysis during combined treatment with pravastatin and gemfibrozil. A case report. G Gerontol 1996; 44: 399-402.
  71. Decoulx E, et al. Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase. Ann Cardiol Angeiol (Paris) 1993; 42: 267-269.
  72. Alderman CP. Possible interaction between nefazodone and pravastatin (letter). Ann Pharmacother 1999; 33: 871.
  73. Raimondeau J, et al. Biologic myolysis during combined fenofibrate-pravastatin therapy. Presse Med 1992; 21: 663-664.
  74. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simva-statin in a renal transplant patient (letter). Am J Med 2000; 108: 351-352.
  75. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals (letter). Arch Dermatol 1996; 132: 1254.
  76. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin (letter). Ann Intern Med 1991; 114: 342.
  77. Bertrand F, et al. [Acute rhabdomyolysis during treatment with simva-statin (Zocor)] (letter). Therapie 1992; 47: 442.
  78. Chariot P, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94: 109-110.
  79. Alvarez JM, et al. Rhabdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin. J Thorac Cardiovasc Surg 1998; 116: 654-655.
  80. Tal A, et al. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997; 90: 546-547.
  81. Van Puijenbroek EP, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403-404.
  82. Blaison G, et al. [Rhabdomyolysis caused by simvastatin in a patient following heart transplantation and cyclosporine therapy.]. Rev Med Intern 1992; 13: 61-63.
  83. Mogyorosi A, et al. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599-602.
  84. Bizarro N, et al. Massive rhabdomyolysis and simvastatin (letter). Clin Chem 1992; 38: 1504.
  85. Dromer C, et al. Rhabdomyolysis due to simvastatin. [Apropos of a case with review of the literature]. Rev Rheum Mal Osteoartic 1992; 59: 281-283.
  86. Jacobson RH, et al. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone (letter). JAMA 1997; 277: 296-297.
  87. Bielecki JW, et al. [Rhabdomyolysis and cholestatic hepatitis treated with simvastatin and chlorzoxazone]. Schweiz Med Wochenschr 1999; 129: 512-518.
  88. Segaert MF, et al. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996; 11: 1846-1847.
  89. Schmassmann-Suhijar D, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929-1930.
  90. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22: 295-297.
  91. Meier C, et al. [Rhabdomyolysis in patients treated with simvastatin and cyclosporine: role of hepatic cytochrome P450 enzyme system activity.]. Schweiz Med Wochenschr 1995; 125: 1342-1346.
  92. Wombolt DG, et al. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin. J Clin Pharmacol 1999; 39: 310-312.
  93. Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13.
  94. Chucrallah A, et al. Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study. Eur Neurol 1992; 32: 293-296
  95. London SF, et al. Cholesterol-lowering agent myopathy (CLAM). Neurology 1991; 41: 1159-1160.
  96. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81 (4A).: 60-64. B.
  97. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-162.
  98. Alejandro DS, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol 1994; 5: 153-160.
    99.
Precedente
Indice